NYSE: ARNA - Arena Pharmaceuticals, Inc.

Altı ay boyunca karlılık: 0%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Arena Pharmaceuticals, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc., биофармацевтическая компания, специализируется на предоставлении новых лекарств с фармакологией и фармакокинетикой пациентам во всем мире.

daha fazla ayrıntı
Его исследовательские клинические программы включают этразимод (APD334), который проходит III фазу клинических испытаний язвенного колита, клинические испытания фазы IIb \ u002FIII при болезни Крона и клинические испытания фазы IIb при атопическом дерматите; Олоринаб (APD371), который проходит фазу IIb клинических испытаний для лечения боли в животе, связанной с синдромом раздраженного кишечника; и APD418, который проходит фазу I клинических испытаний по поводу острой сердечной недостаточности. Он также разрабатывает ралинепаг (APD811), который проходит III фазу клинических испытаний по лечению легочной артериальной гипертензии. Компания имеет соглашения о сотрудничестве с United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Берингер Ингельхайм Интернэшнл ГмбХ; и Eisai Co., Ltd. и Eisai Inc. Arena Pharmaceuticals, Inc. была основана в 1997 году и базируется в Сан-Диего, Калифорния.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2000-07-28
ISIN US0400476075
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.arenapharm.com
Цена ао 93.96
Günlük fiyat değişimi: 0% (99.99)
Haftalık fiyat değişimi: 0% (99.99)
Aylık fiyat değişimi: 0% (99.99)
3 ayda fiyat değişimi: 0% (99.99)
Altı ayda fiyat değişimi: 0% (99.99)
Yıllık fiyat değişimi: 0% (99.99)
3 yılda fiyat değişimi: +6.42% (93.96)
5 yılda fiyat değişimi: +59.3% (62.77)
10 yılda fiyat değişimi: +2 193.35% (4.36)
Yılbaşından bu yana fiyat değişimi: 0% (99.99)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 112540 1
P/BV 9.16 1
P/E 0 0
EV/EBITDA 0.3315 10
Toplam: 4.13

Yeterlik

İsim Anlam Seviye
ROA, % -62.41 0
ROE, % -70.3 0
Toplam: 3.33

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0745 10
Toplam: 9.2

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -119.44 0
karlılık Ebitda, % 324.81 10
karlılık EPS, % 1506.4 10
Toplam: 8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
FIL Fund Management Limited 546513993 7.52
Grandeur Peak Global Advisors, LLC 376351000 5.18
Fidelity Investment Services Ltd 173948600 2.39
Matthews International Cap Mgmt LLc 53015500 0.73
McInroy & Wood Ltd 52000000 0.72
Coupland Cardiff Asset Management LLP 48183500 0.66
Dimensional Fund Advisors 37990200 0.52
First Sentier Investors (UK) Funds Ltd 36895900 0.51
McInroy & Wood Ltd 27000000 0.37
Dimensional Fund Advisors LP 21361352 0.29
Allianz Global Investors Asia Pacific Limited 20787200 0.29
Danske Bank Asset Management 18482893 0.25
Aberdeen Standard Investments (Asia) Limited 14519600 0.2
Fidelity Investments Asset Management 13917900 0.19
Mondrian Investment Partners Ltd 13603001 0.19
J O Hambro Capital Management Limited 10884976 0.15
JOM Rahastoyhtiö Oy/ Fund Management Ltd 8000000 0.11
Nikko Asset Management Asia Limited 6966300 0.1
Degroof Petercam Asset Services S.A. 6493524 0.09
Mitsubishi UFJ Kokusai Asst Mgmt Co.,Ltd 2528500 0.03
Edmond de Rothschild Asset Management (Lux) 2318329 0.03
FIL Gestion 1661058 0.02
Dimensional Fund Advisors Ltd 1646000 0.02
John Hancock Investment Management LLC 1453600 0.02
PT Ashmore Asset Management Indonesia 1303600 0.02
MAAKL Mutual Berhad 565400 0.01
Segall Bryant & Hamill 481700 0.01
T&D Asset Management Co Ltd 288500 0
Maybank Asset Management Singapore Pte. Ltd 193500 0
Fidelity (FIL Inv Mgmt (Lux) S.A.) 22600 0
Fidelity (FIL Fund Management Limited) 0 0

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
MicroSectors Cannabis 2X Leveraged ETN 2.36 88.65
ProShares UltraShort Nasdaq Biotechnology 0.28 -40.36 1.76
SPDR S&P Emerging Markets Small Cap ETF 0.00994 5.46 3.03583
Dimensional Emerging Markets Core Equity 2 ETF 0.00325 15.96 3.34087
0.6617.432.04



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Amit D. Munshi M.B.A. Pres & CEO 1.22M 1968 (57 yıllar)
Ms. Laurie D. Stelzer Exec. VP & CFO 630.76k 1968 (57 yıllar)
Mr. Vincent E. Aurentz Exec. VP & Chief Bus. Officer 692.82k 1968 (57 yıllar)
Mr. Robert Lisicki Exec. VP & Chief Commercial Officer 686.63k 1968 (57 yıllar)
Megan E. Knight Director of Investor Relations N/A
Patrick Malloy VP of Investor Relations & Corp. Communications N/A
Dr. Christopher H. Cabell FACC, M.D., MHS Advisor 687.1k
Dr. Douglas A. Bakan Ph.D. Exec. VP of Technical Operations N/A
Dr. Lamine Mbow Ph.D. Sr. VP & Chief Scientific Officer N/A
Mr. Michael E. Paolucci Exec. VP of HR N/A 1960 (65 yıllar)

Adres: United States, Park City, UT , 136 Heber Avenue - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: http://www.arenapharm.com